1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Multiple sclerosis

Ocrelizumab for treating relapsing–remitting multiple sclerosis

Technology appraisal guidance [TA533] Published: 25 July 2018

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 230 KB 25 July 2018  

Final appraisal determination

  • Final appraisal determination  
  • Final appraisal determination document PDF 504 KB 22 June 2018  
  • Public committee slides PDF 436 KB 22 June 2018  
  • Committee papers PDF 4.43 MB 22 June 2018  

Draft guidance

  • Draft guidance  
  • Appraisal consultation document PDF 428 KB 05 April 2018  
  • Public committee slides PDF 1.03 MB 05 April 2018  
  • Committee papers PDF 22.75 MB 05 April 2018  

Invitation to participate

  • Final scope PDF 109 KB 03 October 2017  
  • Final matrix PDF 252 KB 03 October 2017  
  • Equality impact assessment (Scoping) PDF 174 KB 26 September 2017  
  • NICE's response to comments on the draft scope and provisional matrix PDF 490 KB 03 October 2018  

Draft scope documents

  • Draft scope (pre-referral) PDF 131 KB 31 January 2017  
  • Provisional matrix (pre-referral) PDF 37 KB 31 January 2017